Evidence map›Paper›PMID 42763549›Full record

ArticleNew microbes and new infections2026

Comparable severity of

Livia Bresciani, Mariasilvia Guardiani, Manuel Rojas-Blasquez, Edgar Ramirez, Salvatore Iaquinandi, Cesar Martel, Miguel Velarde-Mera, Samar Sifuentes-Vidigal, Anna Carraro, Gianluca Russo and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Livia BrescianiInfectious Diseases Unit, Sapienza of Rome, Rome, Italy.
Mariasilvia GuardianiDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Manuel Rojas-BlasquezFaculty of Medicine, National University of the Peruvian Amazon, Iquitos, Peru.
Edgar RamirezFaculty of Medicine, National University of the Peruvian Amazon, Iquitos, Peru.
Salvatore IaquinandiInfectious Diseases Unit, Sapienza of Rome, Rome, Italy.
Cesar MartelMedipeace, Project Assistant, Iquitos, Peru.
Miguel Velarde-MeraFaculty of Medicine, National University of the Peruvian Amazon, Iquitos, Peru.
Samar Sifuentes-VidigalFaculty of Medicine, National University of the Peruvian Amazon, Iquitos, Peru.
Anna CarraroSapienza University of Rome, Sant'Andrea Hospital, Department of Infectious Diseases, Rome, Italy.
Gianluca RussoDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Caterina PasquazziInfectious Diseases Unit, Sapienza of Rome, Rome, Italy.
Juan Carlos CelisFaculty of Medicine, National University of the Peruvian Amazon, Iquitos, Peru.
Martin Casapia MoralesFaculty of Medicine, National University of the Peruvian Amazon, Iquitos, Peru.
Emanuele NicastriNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy.
César Ramal AsayagFaculty of Medicine, National University of the Peruvian Amazon, Iquitos, Peru.
Miriam LichtnerInfectious Diseases Unit, Sapienza of Rome, Rome, Italy.
Serena VitaInfectious Diseases Unit, Sapienza of Rome, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: We conducted a retrospective hospital-based study at Hospital Regional de Loreto, Iquitos, Peru, from January 1, 2023, to October 30, 2025. The total hospital malaria caseload was determined from records assigned a laboratory-confirmed ICD-10 malaria diagnosis. The analytic cohort comprised hospitalized patients with microscopy-confirmed malaria who received intravenous artesunate because of severe malaria according to the WHO 2022 criteria, or inability to tolerate oral antimalarial treatment. Results: During the study period, 519 laboratory-confirmed malaria diagnoses were recorded in the hospital; of these, 127 patients (24.5%) were hospitalized. Of these, 97 had Conclusions:

Indexed as

Low-transmission settingMalariaPeruvian AmazonPlasmodium vivaxWHO severity criteria

Identifiers

PMID42763549
PMCPMC13589080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.